Compare iShares MSCI United Kingdom (FTSE) (EWU) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs GSK plc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.94, while GSK plc trades at $52.6 (market cap $101.34B). The key difference: GSK plc pays a 3.49% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| EWU | GSK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $61.18 |
52-Week Low | $39.80 | $36.20 |
Market Cap | — | $101.34B |
Enterprise Value | — | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.79, up 1.04% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 62.29. Recent news highlights Middle East tensions impacting European markets, though energy sector gains provide some offset. Key support sits at $46 with resistance at $47.
The outlook remains cautiously optimistic given technical strength, though fundamental data is limited. Risks include geopolitical volatility and broader market sentiment. Investment opportunity hinges on UK economic recovery and energy sector performance amid current market conditions.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
